APO RESEARCH · REPORT
Hidradenitis Suppurativa Treatment
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Product & engineering
Understand the product.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits.
There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.
Selected research
Industry Research
Hidradenitis Suppurativa Treatment Industry Research Report 2026
Market perspective
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits.
There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.
Read the full market overview
The classification of Hidradenitis Suppurativa Treatment includes Medications, Surgery and others, and the proportion of Medications in 2019 is about 76%.
Hidradenitis Suppurativa Treatment is widely used in Hospital, Clinical and other field. The most proportion of Hidradenitis Suppurativa Treatment is Hospital, and the proportion in 2019 is 53.53%.
Europe is the largest consumption place with a consumption market share of 47.76% in 2019. Following Europe, Asia Pacific is the second largest consumption place with the consumption market share of 23.97%.
Market competition is intense. AbbVie, Merck, Pfizer, AstraZeneca, GlaxoSmithKline, etc. are the leaders of the industry.
Report Scope
This report quantifies the global Hidradenitis Suppurativa Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hidradenitis Suppurativa Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hidradenitis Suppurativa Treatment Market by Company
AbbVie
Merck
Pfizer
AstraZeneca
GlaxoSmithKline
Perrigo
Sun Pharma
Almirall
Bausch Health
Johnson & Johnson
Hidradenitis Suppurativa Treatment Segment by Type
Medications
Surgery
Others
Hidradenitis Suppurativa Treatment Segment by Application
Hospitals
Clinics
Others
Hidradenitis Suppurativa Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hidradenitis Suppurativa Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hidradenitis Suppurativa Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hidradenitis Suppurativa Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hidradenitis Suppurativa Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Medications
- Surgery
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- AbbVie
- Merck
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Perrigo
- Sun Pharma
- Almirall
- Bausch Health
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hidradenitis Suppurativa Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Medications
- 2.2.3 Surgery
- 2.2.4 Others
- 2.3 Hidradenitis Suppurativa Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Hidradenitis Suppurativa Treatment Breakdown Data by Type
- 3.1 Global Hidradenitis Suppurativa Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Hidradenitis Suppurativa Treatment Forecasted Market Size by Type (2027-2032)
4 Hidradenitis Suppurativa Treatment Breakdown Data by Application
- 4.1 Global Hidradenitis Suppurativa Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Hidradenitis Suppurativa Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hidradenitis Suppurativa Treatment Market Perspective (2021-2032)
- 5.2 Global Hidradenitis Suppurativa Treatment Growth Trends by Region
- 5.2.1 Global Hidradenitis Suppurativa Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hidradenitis Suppurativa Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Hidradenitis Suppurativa Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Hidradenitis Suppurativa Treatment Market Dynamics
- 5.3.1 Hidradenitis Suppurativa Treatment Industry Trends
- 5.3.2 Hidradenitis Suppurativa Treatment Market Drivers
- 5.3.3 Hidradenitis Suppurativa Treatment Market Challenges
- 5.3.4 Hidradenitis Suppurativa Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hidradenitis Suppurativa Treatment Players by Revenue
- 6.1.1 Global Top Hidradenitis Suppurativa Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Hidradenitis Suppurativa Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Hidradenitis Suppurativa Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hidradenitis Suppurativa Treatment Head Office and Area Served
- 6.4 Global Hidradenitis Suppurativa Treatment Players, Product Type & Application
- 6.5 Global Hidradenitis Suppurativa Treatment Manufacturers Established Date
- 6.6 Global Hidradenitis Suppurativa Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hidradenitis Suppurativa Treatment Market Size (2021-2032)
- 7.2 North America Hidradenitis Suppurativa Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hidradenitis Suppurativa Treatment Market Size by Country (2021-2026)
- 7.4 North America Hidradenitis Suppurativa Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hidradenitis Suppurativa Treatment Market Size (2021-2032)
- 8.2 Europe Hidradenitis Suppurativa Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hidradenitis Suppurativa Treatment Market Size by Country (2021-2026)
- 8.4 Europe Hidradenitis Suppurativa Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hidradenitis Suppurativa Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Hidradenitis Suppurativa Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hidradenitis Suppurativa Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hidradenitis Suppurativa Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hidradenitis Suppurativa Treatment Market Size (2021-2032)
- 10.2 South America Hidradenitis Suppurativa Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hidradenitis Suppurativa Treatment Market Size by Country (2021-2026)
- 10.4 South America Hidradenitis Suppurativa Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hidradenitis Suppurativa Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Hidradenitis Suppurativa Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hidradenitis Suppurativa Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hidradenitis Suppurativa Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AbbVie
- 12.1.1 AbbVie Company Information
- 12.1.2 AbbVie Business Overview
- 12.1.3 AbbVie Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.1.4 AbbVie Hidradenitis Suppurativa Treatment Product Portfolio
- 12.1.5 AbbVie Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.2.4 Merck Hidradenitis Suppurativa Treatment Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.3.4 Pfizer Hidradenitis Suppurativa Treatment Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Company Information
- 12.4.2 AstraZeneca Business Overview
- 12.4.3 AstraZeneca Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.4.4 AstraZeneca Hidradenitis Suppurativa Treatment Product Portfolio
- 12.4.5 AstraZeneca Recent Developments
- 12.5 GlaxoSmithKline
- 12.5.1 GlaxoSmithKline Company Information
- 12.5.2 GlaxoSmithKline Business Overview
- 12.5.3 GlaxoSmithKline Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.5.4 GlaxoSmithKline Hidradenitis Suppurativa Treatment Product Portfolio
- 12.5.5 GlaxoSmithKline Recent Developments
- 12.6 Perrigo
- 12.6.1 Perrigo Company Information
- 12.6.2 Perrigo Business Overview
- 12.6.3 Perrigo Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.6.4 Perrigo Hidradenitis Suppurativa Treatment Product Portfolio
- 12.6.5 Perrigo Recent Developments
- 12.7 Sun Pharma
- 12.7.1 Sun Pharma Company Information
- 12.7.2 Sun Pharma Business Overview
- 12.7.3 Sun Pharma Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.7.4 Sun Pharma Hidradenitis Suppurativa Treatment Product Portfolio
- 12.7.5 Sun Pharma Recent Developments
- 12.8 Almirall
- 12.8.1 Almirall Company Information
- 12.8.2 Almirall Business Overview
- 12.8.3 Almirall Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.8.4 Almirall Hidradenitis Suppurativa Treatment Product Portfolio
- 12.8.5 Almirall Recent Developments
- 12.9 Bausch Health
- 12.9.1 Bausch Health Company Information
- 12.9.2 Bausch Health Business Overview
- 12.9.3 Bausch Health Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.9.4 Bausch Health Hidradenitis Suppurativa Treatment Product Portfolio
- 12.9.5 Bausch Health Recent Developments
- 12.10 Johnson & Johnson
- 12.10.1 Johnson & Johnson Company Information
- 12.10.2 Johnson & Johnson Business Overview
- 12.10.3 Johnson & Johnson Revenue in Hidradenitis Suppurativa Treatment Business (2021-2026)
- 12.10.4 Johnson & Johnson Hidradenitis Suppurativa Treatment Product Portfolio
- 12.10.5 Johnson & Johnson Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst